Skip to content

The Role of Oxidative Stress in the Cardiovascular Consequences of Sleep Apnea

The Role of Oxidative Stress in the Cardiovascular Consequences of Sleep Apnea

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00701441
Enrollment
25
Registered
2008-06-19
Start date
2007-02-28
Completion date
2010-06-30
Last updated
2013-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sleep Apnea

Keywords

sleep apnea,, oxidative stress

Brief summary

Obstructive Sleep Apnea (OSA) is the most common sleep disorder affecting up to 9-24 percent of middle aged adults, and is becoming increasingly implicated in the pathogenesis of hypertension, and other cardiovascular disorders. Up to half of patients with OSA have hypertension, and their risk of developing hypertension increases with the increasing severity of Sleep Apnea. Patients with OSA and no hypertension have endothelial dysfunction, which is believed to be the precursor for most cardiovascular disorders. The upper airway collapse and obstruction that occur in OSA result in a pattern of intermittent hypoxia, that has been shown to be the cause of the hypertension, and endothelial dysfunction found in patients with OSA. Intermittent hypoxia results in oxidative stress, which in turn is linked to the pathogenesis of hypertension and endothelial dysfunction. This protocol evaluates the role of the oxidative stress in endothelial function and blood pressure in patients with OSA. This is a pilot clinical study that will compare oxidative stress parameters, and endothelial function in patients with OSA before starting treatment with continuous positive airway pressure (CPAP) and 12 weeks post being on CPAP. These patients will be compared to control patients with no history of OSA. the study does not involve assignement to different treatments. All patients will receive the indicated treatment for OSA and measurements will be collected before and 12 weeks after adequate treatment.

Detailed description

Obstructive Sleep Apnea (OSA) is increasingly recognized as a cardiovascular risk factor. OSA is a cause of hypertension and has strong association with atherosclerosis, coronary heart disease, diabetes stroke , and fatal cardiovascular events. Endothelial dysfunction is a preclinical vascular abnormality that predicts subsequent development of vascular disease . Patients with OSA demonstrate endothelial dysfunction in the absence of any manifested vascular disease . The mechanism of endothelial dysfunction in OSA is largely unknown. Endothelial dysfunction in OSA is reversible with antioxidants, suggesting a role for oxidant overproduction in the decreased NO availability in OSA. This provides parallels to other cardiovascular diseases in which oxidative stress induced endothelial dysfunction is important. Recent studies reported evidence of dysfunction or decreased expression of endothelial nitric oxide synthase (eNOS) in association with increased peroxynitrite in harvested venous endothelial cells of OSA patients. We endeavored to perform the first direct quantification of microvascular endothelial genes from OSA patients. We hypothesized that patients with OSA who are free of any cardiovascular disease will have early functional changes in the microcirculatory endothelial cells that are associated with OSA, and therefore would resolve with treatment. Given the role of oxidative stress in the vascular disease of OSA, we expected to find evidence of superoxide overproduction in the microcirculatory vessels. We expected these functional changes to be reversible with treatment of OSA. Measurement of superoxide will be done on the subcutaneous biopsy tissue using quantitative Polymerase Chain Reaction (qPCR) and immunohistochemistry techniques and image analysis software. Measurement of endothelial function will be done using Doppler ultrasound.

Interventions

None listed

Sponsors

Rami Khayat
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Completed sleep study - Older than 18

Exclusion criteria

* Hypertension * Diabetes * coronary disease * Peripheral vascular disease * High cholesterol * Smoking * Pregnancy * Use of erectile dysfunction medications or supplements

Design outcomes

Primary

MeasureTime frameDescription
Flow Mediated DilationBaseline and 12 weeksA non-invasive test using an ultrasound to measure baseline resting vessel diameter and vessel wall dilation in upper arm post application of an inflated blood pressure cuff for five minutes. The percentage change in vessel wall dilation due to stimulation from the resting vessel diameter will be calculated for each group of participants. The results will be compared relative to each group of participants.

Other

MeasureTime frameDescription
Peroxynitrite Deposition in the Vascular Wallsbaseline and 12 weeksA forearm biopsy will be collected to isolate human microcirculatory endothelial cells. The stain density of peroxynitrite, an indicator of oxidative stress, in the vascular walls is compared between pre-treatment and post treatment patient tissue. Also another comparison is made between pre-treatment and control tissue. The stain density is a software-generated measurement of pixel intensity and is considered to be an arbitrary unit. Higher numbers indicate greater density

Countries

United States

Participant flow

Participants by arm

ArmCount
Control
No diagnosis of Obstructive Sleep Apnea or treatment with continuous positive airwary therapy
9
Obstructive Sleep Apnea
Participants wear continuous positive airway therapy
16
Total25

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall Studyfailure in cpap compliance04

Baseline characteristics

CharacteristicObstructive Sleep ApneaControlTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
16 Participants9 Participants25 Participants
Age Continuous43.6 years
STANDARD_DEVIATION 11.2
32.2 years
STANDARD_DEVIATION 7.4
39.5 years
STANDARD_DEVIATION 11.3
Region of Enrollment
United States
16 participants9 participants25 participants
Sex: Female, Male
Female
4 Participants5 Participants9 Participants
Sex: Female, Male
Male
12 Participants4 Participants16 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 90 / 16
serious
Total, serious adverse events
0 / 90 / 16

Outcome results

Primary

Flow Mediated Dilation

A non-invasive test using an ultrasound to measure baseline resting vessel diameter and vessel wall dilation in upper arm post application of an inflated blood pressure cuff for five minutes. The percentage change in vessel wall dilation due to stimulation from the resting vessel diameter will be calculated for each group of participants. The results will be compared relative to each group of participants.

Time frame: Baseline and 12 weeks

Population: Comparative values analyzed for those with endothelial nitric oxide synthase and nitrotyrosine stain density values only.

ArmMeasureValue (MEAN)Dispersion
Obstructive Sleep Apnea-pre TreatmentFlow Mediated Dilation5.7 percentage change of vessel diamterStandard Error 0.5
ControlFlow Mediated Dilation9.5 percentage change of vessel diamterStandard Error 0.6
Obstructive Sleep Apnea Post TreatmentFlow Mediated Dilation7.3 percentage change of vessel diamterStandard Error 0.9
Comparison: Flow mediated dilation = \[(average maximum dilation post cuff deflation - average baseline diameter)/ average baseline diameter\]100p-value: 0.02t-test, 2 sided
Other Pre-specified

Peroxynitrite Deposition in the Vascular Walls

A forearm biopsy will be collected to isolate human microcirculatory endothelial cells. The stain density of peroxynitrite, an indicator of oxidative stress, in the vascular walls is compared between pre-treatment and post treatment patient tissue. Also another comparison is made between pre-treatment and control tissue. The stain density is a software-generated measurement of pixel intensity and is considered to be an arbitrary unit. Higher numbers indicate greater density

Time frame: baseline and 12 weeks

Population: Comparative values analyzed for those with endothelial nitric oxide synthase and flow mediated dilation only.

ArmMeasureValue (MEAN)Dispersion
Obstructive Sleep Apnea-pre TreatmentPeroxynitrite Deposition in the Vascular Walls44.0 stain density unitsStandard Error 1.6
ControlPeroxynitrite Deposition in the Vascular Walls21.8 stain density unitsStandard Error 1.9
Obstructive Sleep Apnea Post TreatmentPeroxynitrite Deposition in the Vascular Walls30.5 stain density unitsStandard Error 1.6
Comparison: For comparing pre- versus post-treatment, paired t tests were used. For each variable and comparison, we tested at the 0.05 level with double-sided P values.p-value: 0.02t-test, 2 sided

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026